



Final Results

Year Ended December 31, 2018


Financial

- ✓ Total revenues 9.8% lower at £3.05m (Biomarker Services £0.75m)
- ✓ Continued strong growth (+ 10.2%) in TMT[®] sales & royalties
- ✓ Reduced operating costs (- 13.3%) through consolidation & cost containment
- ✓ Received £1m loan facility from Vulpes (largest shareholder)
- ✓ Maintained year end cash reserves at £0.96m
- ✓ Resolved R&D tax credit claims from previous years

Operational

- ✓ Extended exclusive licence with Thermo Scientific to include higher-plex TMT[®] IP
- ✓ Engaged EU sales agent – Cenibra GmbH
- ✓ Broadened customer base (>30 service orders) - significant US & repeat business
- ✓ Reported new Super Depletion method at ATS with Pliant Therapeutics Inc.
- ✓ Recertified ISO 9001:2015 QMS and GCLP accreditation

Key Metric \ Year	2018	2017	% annual growth
Sales	£0.75m	£0.79m	(5.5%)
Quotes	57	16	250%
Order value	£1.0m	£0.44m	125%
Initiated Projects	32	13	145%



Q1 Update

- ✓ Completed synthesis of higher-plex TMT® tags ahead of 2019 launch
- ✓ Received largest ever Q1 TMT® order from Thermo
- ✓ Achieved ~120% YoY growth in Q1 service revenues
- ✓ Issued 24 project quotes
- ✓ Signed license agreement with Galaxy CCRO Inc. for GST-P stroke biomarker

Focus

- Broaden range of services/workflows
- Identify opportunities in evolving AI market
- Increase commercial resources
- Support launch of higher-plex TMT®
- Pursue strategic partnerships and collaborative agreements